文献速递产科母胎医学

尿液胎盘生长因子预测高危妊娠胎盘不良结局

Urinary Placental Growth Factor for Prediction of Placental Adverse Outcomes in High-Risk Pregnancies.
PubMed 文献 · Obstet Gynecol · 2019-01-01

本研究为Heparin-Preeclampsia随机试验的预计划辅助研究,纳入187例有早发型重度子痫前期病史孕妇,比较低分子肝素加阿司匹林组与单用阿司匹林组。两组<34周复合不良结局无显著差异,但孕中期尿PlGF/肌酐在发生复合不良结局者中显著降低,假阳性率10%时灵敏度75.2%(AUC 0.93)。

要点

  • 孕22-26周尿PlGF/肌酐在<34周发生复合不良结局者中显著低于未发生者。
  • 低分子肝素加阿司匹林与单用阿司匹林相比,尿PlGF水平无显著差异。
  • 假阳性率10%时,孕中期尿PlGF预测<34周复合不良结局的灵敏度为75.2%(AUC 0.93)。

核心结论

  • 孕中期(22-26周)尿PlGF降低与随后<34周发生子痫前期相关不良结局相关。

研究设计与样本

  • Heparin-Preeclampsia随机试验的预计划辅助研究,纳入有早发型重度子痫前期(<34周)病史孕妇187例。
  • 母研究所有孕妇均接受阿司匹林治疗,随机分为低分子肝素加阿司匹林组(n=93)与单用阿司匹林组(n=94)。
  • 在孕10-13 6/7、14-17 6/7、18-21 6/7、22-25 6/7、26-29 6/7、30-33 6/7及34-37 6/7周窗口检测尿PlGF与尿肌酐。

主要发现

  • 两组<34周复合不良结局(子痫前期、胎儿生长受限、胎盘早剥、围产期死亡、孕产妇死亡)发生率相似:低分子肝素加阿司匹林组14/93(15.1%)vs 单用阿司匹林组11/94(11.7%),P=.50。
  • 低分子肝素加阿司匹林组与单用阿司匹林组尿PlGF水平无显著差异。
  • 孕中期(22-26周)尿PlGF/肌酐中位数[四分位距]在<34周发生复合不良结局者中为42.7[32.4-80.8] pg/mg,显著低于未发生者的255.6[118.7-391.8] pg/mg,P<.001。
  • 孕中期尿PlGF/肌酐在<34周发生子痫前期者中为42.7[27.5-80.7] pg/mg,显著低于未发生者的244.6[112.9-390.6] pg/mg,P<.001。
  • 假阳性率固定为10%时,孕中期尿PlGF预测随后发生复合不良结局的灵敏度为75.2%(曲线下面积0.93)。

关键数值与推荐

  • 复合不良结局定义:子痫前期、胎儿生长受限、胎盘早剥、围产期死亡、孕产妇死亡,发生于<34周妊娠。
  • 孕中期尿PlGF/肌酐在<34周复合不良结局组为42.7[32.4-80.8] pg/mg vs 无复合不良结局组255.6[118.7-391.8] pg/mg,P<.001。
  • 孕中期尿PlGF/肌酐在<34周子痫前期组为42.7[27.5-80.7] pg/mg vs 无子痫前期组244.6[112.9-390.6] pg/mg,P<.001。
  • 假阳性率10%时,孕中期尿PlGF预测<34周复合不良结局的灵敏度75.2%,AUC 0.93。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate whether urinary levels of placental growth factor (PlGF) during pregnancy are associated with the subsequent development of composite adverse outcomes (preeclampsia, fetal growth restriction, placental abruption, perinatal death, maternal death) occurring at less than 34 weeks of gestation. METHODS: This is a preplanned ancillary study of the Heparin-Preeclampsia trial, a randomized trial in pregnant women with a history of severe early-onset preeclampsia (less than 34 weeks of gestation). In the parent study, all women were treated with aspirin and then randomized to receive either low-molecular-weight (LMW) heparin or aspirin alone. For this substudy we measured urinary levels of PlGF and urinary creatinine at the following gestational windows: 10-13 6/7, 14-17 6/7, 18-21 6/7, 22-25 6/7, 26-29 6/7, 30-33 6/7, and 34-37 6/7 weeks of gestation. RESULTS: Urine samples were available from 187 patients: LMW heparin plus aspirin (n=93) and aspirin alone (n=94). The two groups had comparable baseline characteristics and had similar adverse composite outcomes at less than 34 weeks of gestation (14/93 [15.1%] vs 11/94 [11.7%]; P=.50). There were no significant differences in urine PlGF levels in the patients who received LMW heparin plus aspirin compared with those who received aspirin alone. However, median [interquartile range] urinary PlGF/creatinine concentrations (pg/mg) measured at mid-pregnancy (22-26 weeks of gestation) were significantly lower among women who developed composite adverse outcome at less than 34 weeks of gestation (42.7 [32.4-80.8] vs 255.6 [118.7-391.8] P<.001) and significantly lower among women who developed preeclampsia at less than 34 weeks of gestation (42.7 [27.5-80.7] vs 244.6 [112.9-390.6] P<.001). For a fixed false-positive rate of 10% the sensitivity of urinary PlGF concentrations at mid-pregnancy was 75.2% (area under the curve 0.93) for the subsequent development of composite adverse outcomes. CONCLUSION: Decreased urinary PlGF at mid-gestation (22-26 weeks of gestation) is associated with the subsequent development of preeclampsia-related adverse outcomes at less than 34 weeks of gestation. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT00986765.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Lecarpentier E, Gris JC, Cochery-Nouvellon E, et al. Urinary Placental Growth Factor for Prediction of Placental Adverse Outcomes in High-Risk Pregnancies. Obstet Gynecol. 2019. PMID: 31764746. doi:10.1097/AOG.0000000000003547

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。